ANTIOXIDATIVE EFFICACY OF NEUROPROTECTIVE THERAPY IN PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA

The aim of the research is to estimate the molecular and biochemical efficacy of Tiocetam administration to patients with ChCI, with regard of the state of glutathione system in plasma and of erythrocytes hemolysate. 60 patients with ChCI, averagely aged 54,70±7,71 years, were examined and divided into two groups of 30 people each, depending on the treatment regimen. The patients from the control group were intravenously administered infusions of Tiocetam with the dosage of 20 ml (for 10 days, then changed for Tiocetam forte (400 mg of Piracetam and 100 mg of Tiotriazoline) with the dosage of 1 pill thrice a day during 30 days. The patients of the experimental group were taking basic treatment, without administration of neuroprotective drugs. Concentration of renewed glutathione (RG) in blood plasma and erythrocytes hemolysate of patients was defined according to the reaction with ortho-phthalic anhydride; the contents of SH-group thioles in blood plasma, the activity of glutathione-dependent enzymes were defined spectrophotometrically. Treating patients with ChCI with Tiocetam has revealed probable (by Friedman test) decreased activity of glutathione transferase (GT) (p=0,003), and increased activity of glutathione reductase (GR) (p=0,002) and glutathione peroxidase (GPx) (p=0,002) in blood plasma, as well as decreased activity of GT (p=0,004), increased activity of GR (p=0,007) and GPx (p<0,001), as well as an increase of RG (p<0,001) in erythrocytes hemolysate of the patients with ChCI. Obtained results prove pathogenetically substantiated administration of Tiocetam for patients with ChCI, due to its positive impact on the condition of glutathione antioxidative system in blood plasma and erythrocytes hemolysate, by means of suppression of main mechanisms of oxidative stress, which make preconditions for clinical manifestations of ChCI.